Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

CYTR $5.01 0.5100 +11.33%
ONCY $0.76 0.0710 +10.29%
FATE $5.96 0.5500 +10.17%
FPRX $24.16 1.6600 +7.38%
AVEO $1.84 0.1200 +6.98%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

BPTH $1.44 -0.1200 -7.69%
KERX $11.45 -0.8300 -6.76%
SNSS $2.64 -0.1800 -6.38%
BDSI $9.46 -0.5600 -5.59%
CLVS $86.15 -4.8400 -5.32%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | Next > | Last >>

Personalized Cancer Vaccines Have Already Helped Treat Three Patients

(Washington Post/Speaking of Science blog) Apr 3, 2015 - One day, cancer treatment regimens might include vaccines specially tailored to each patient. In a small preliminary study published Thursday in Science, researchers report successful use of these vaccines in three patients.
read article (free subscription required) 

European Commission Approves Amgen's Vectibix® (panitumumab) As First-Line Treatment In Combination With FOLFIRI Chemotherapy For Metastatic Colorectal Cancer

(Amgen) Apr 6, 2015 - Amgen today announced that the European Commission approved a new use of Vectibix® (panitumumab) as first-line treatment in combination with FOLFIRI for the treatment of adult patients with wild-type (WT) RAS metastatic colorectal cancer (mCRC).
read corporate press release 

FDA Issues Final Guidance on the Evaluation and Labeling of Abuse-Deterrent Opioids

( Apr 1, 2015 - The U.S. Food and Drug Administration today issued a final guidance to assist industry in developing opioid drug products with potentially abuse-deterrent properties.
read press release 

Experimental Ebola Vaccine Licensed By Merck, NewLink Passes Early-Stage Trials

(International Business Times) Apr 2, 2015 - An experimental Ebola vaccine backed by the U.S. military has shown “robust” effectiveness in stopping the spread of the disease, a U.S. Army research lab announced Wednesday.
read article 

Pfizer to Cease Vaccine Commercial Operations in China

(Bloomberg) Apr 1, 2015 - Pfizer Inc. is ceasing its vaccine commercial operations in China after the government failed to renew its license for a key shot for children, the latest sign of the uncertainties facing international drugmakers in the nation.
read article 

Prenatal Tests Prove Accurate, But Come with Cautions: Study

(NY Daily News/Reuters) Apr 2, 2015 - A Roche blood test to screen fetuses for Down syndrome worked far better than standard prenatal screening tests in younger, low-risk women, U.S. researchers said on Wednesday, setting the stage for more widespread use.
read article 

Should FDA Penalize Drug Makers Over Diabetes Drug Ads?

(Wall Street Journal/Pharmalot blog) Apr 1, 2015 - A consumer watchdog has asked the FDA to stop several drug makers from promoting their diabetes medicines for losing weight, because the drugs were not approved for this purpose.
read article (paid subscription required) 

Medicare SGR Formula Triggers 21% Pay Cut Today

(Medscape Medical News) Apr 1, 2015 - Today is April Fools' Day, but for physicians, it also could be called Day One of Medicare Payment Limbo.
read article (free registration required) 

Cold Spring Harbor Lab, Seeking Human Subjects, Teams Up With Hospital System

(New York Times) Apr 2, 2015 - Some of the world’s finest scientists live in a former whaling village on the North Shore of Long Island, in a compound reminiscent of an army post.
read article 

March Madness: Submitting Abstracts to Multiple Meetings

(Medscape Medical News) Apr 1, 2015 - Dr Bruce Cheson discusses the pros and cons of investigators submitting the same data to multiple meetings.
read article (free registration required) 

Biotech Stock Mailbag: Northwest Bio, Intrexon, Ziopharm

(TheStreet) Apr 2, 2015 - Welcome to the pre-Passover/Easter Biotech Stock Mailbag. May you get your fill of matzoh and Peeps this weekend.
read article 

OncoMed and Lilly Enter Clinical Supply Agreement to Evaluate the Combination of Demcizumab and Alimta(R) (pemetrexed for injection) in Lung Cancer

(OncoMed) Apr 2, 2015 - OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, announced today that it has entered into an agreement with Eli Lilly and Company.
read corporate press release 

Augmenix Announces FDA Clearance of SpaceOAR® System

(Yahoo! Finance) Apr 2, 2015 - Augmenix, Inc., a privately held company developing minimally invasive hydrogel products to improve outcomes following cancer radiotherapy, today announced FDA clearance of the SpaceOAR® System, the first product in the United States cleared as a spacer to protect the rectum in men undergoing prostate cancer (PCa) radiotherapy.
read article 

American Cancer Society Announces Gary M. Reedy As Its Next Chief Executive Officer

(ACS) Apr 2, 2015 - The American Cancer Society today announced that Gary M. Reedy has been selected by the Society's Board of Directors as its next chief executive officer, effective April 27, 2015.
read press release 

Heron Therapeutics Reaches Target Patient Enrollment in MAGIC Phase 3 Study of SUSTOL®

(MarketWatch) Apr 2, 2015 - Heron Therapeutics, Inc, a biotechnology company, today announced that it has reached its enrollment target in MAGIC (Modified Absorption Granisetron In the Prevention of Chemotherapy induced nausea and vomiting (CINV)) and is in the process of closing enrollment of new patients at its clinical sites.
read article 

Enzalutamide Demonstrates Statistically Significant Improvement in Progression Free Survival Compared With Bicalutamide in Strive Trial

(Morningstar) Apr 2, 2015 - Medivation, Inc. and Astellas Pharma Inc. today announced topline results from the Phase 2 STRIVE trial comparing enzalutamide with bicalutamide in a study population of men with non-metastatic or metastatic castration-resistant prostate cancer.
read article 

High-Cost Imaging Falls Short for DLBCL Monitoring

(MedPage Today) Apr 1, 2015 - Routine CT or PET-CT scans offer minimal survival benefit at substantial economic costs.
read article (free registration required) 

Key Mechanism Identified in Pediatric Bone Cancers That Allows Proliferation of Tumor-Forming Stem Cells

(NYU Langone Medical Center) Apr 2, 2015 - A particular molecular pathway permits stem cells in pediatric bone cancers to grow rapidly and aggressively, according to researchers.
read press release 

Metformin Use Associated With Less CRC Risk in U.S. Population

(Doctors Lounge/HealthDay News) Apr 1, 2015 - For patients with diabetes in the United States, metformin use is associated with reduced risk of developing colorectal cancer, according to a study published in the April 1 issue of Cancer.
read article 

Excess Weight Early in Life Linked to Colon Cancer Risk in Women

(U.S. News & World Report/HealthDay News) Apr 2, 2015 - Women who were overweight as children and teens may have a greater risk of colon cancer, no matter what their current weight, a new study cautions.
read article 

Colorectal Cancer Increases With Age in Screening Group

(Medscape Medical News) Apr 2, 2015 - Among patients undergoing surveillance colonoscopy, researchers saw a trend for increased colorectal cancer (CRC) diagnoses among those aged 70 years or older compared with adults aged 55 to 69 years.
read article (free registration required) 

New Data Revive Prostate Cancer Active Surveillance Debate

(Medscape Medical News) Apr 1, 2015 - Active surveillance for men with low-risk prostate cancer reduces overtreatment, but it could also mean that some men miss the opportunity for cure, according to the Göteborg randomized population-based prostate cancer screening trial.
read article (free registration required) 

Insurers, Providers Experiment With New Oncology Payment Models

(AIS Health/ACO Business News) Apr 2, 2015 - Insurers and provider groups are trying a variety of approaches on oncology reimbursement that will remove the incentive for oncologists to use expensive but not necessarily effective chemotherapy drugs and instead place the focus back on quality of care.
read article 

More Support for PARP Inhibitor in Ovarian Cancer

(MedPage Today) Apr 1, 2015 - Patients with relapsed, heavily pretreated, BRCA-positive ovarian cancer had durable responses to treatment with the PARP inhibitor olaparib (Lynparza), a post hoc analysis of clinical trial data showed.
read article (free registration required) 

The Slow, Steady Battle To Fix Cancer Care

(Forbes) Apr 1, 2015 - After a cancer patient's first 30 days in the American medical system, the bills start stacking up—right next to the pile of paperwork explaining benefits. "It's very hard for patients to match these things up," says Dr. Thomas W. Feeley, who recently joined the Harvard Business School faculty as a senior fellow to study health-care reform.
read article